Loading...
Loading...
CTLT| Name | Value |
|---|---|
| Revenues | 1,037.0M |
| Cost of Revenue | 857.0M |
| Gross Profit | 180.0M |
| Operating Expense | 205.0M |
| Operating I/L | -25.0M |
| Other Income/Expense | -47.0M |
| Interest Income | 51.0M |
| Pretax | -282.0M |
| Income Tax Expense | -55.0M |
| Net Income/Loss | -227.0M |
Catalent, Inc. develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products globally. The company operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. It provides formulation, development, and manufacturing services for soft capsules, prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. Catalent also offers biologic cell-line development, cell therapy and viral-based gene therapy, formulation, development, and manufacturing for parenteral dose forms, and clinical supply services for pharmaceutical, biotechnology, and consumer health companies, as well as companies in other healthcare market segments.
